Background Image
Previous Page  170 / 182 Next Page
Information
Show Menu
Previous Page 170 / 182 Next Page
Page Background

169

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

227

Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer

pain [Brief]. Br Med J 2008; 337: a3104.

228

Schechter NL, Weisman SJ, Rosenblum M, Bernstein B, Conard PL. The use of oral

transmucosal fentanyl citrate for painful procedures in children. Pediatrics 1995; 95(3):

335-339.

229

Schutzman SA, Burg J, Liebelt E, Strafford M, Schechter N, Wisk M, Fleisher G. Oral

transmucosal fentanyl citrate for premedication of children undergoing laceration

repair. Ann Emerg Med 1994; 24(6): 1059-1064.

230

Shaiova L, Lapin J, Manco LS, Shasha D, Hu K, Harrison L, Portenoy RK. Tolerability and

effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in pati-

ents with radiation-induced oral mucositis. Support. Care Cancer 2004; 12(4): 268-273.

231

Sharar SR, Bratton SL, Carrougher GJ, Edwards WT, Summer G, Levy FH, Cortiella J. A

comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient

pediatric burn wound care analgesia. J Burn Care Rehabil 1998; 19(6): 516-521.

232

Sharar SR, Carrougher GJ, Selzer K, O'Donnell F, Vavilala MS, Lee LA. A comparison of

oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound

care. J. Burn Care Rehabil 2002; 23(1):27-31.

233

Skinner C, Thompson E, Davies A. Clinical features. In: Davies A (Hrsg.), Cancer-related

breakthrough pain. Oxford: Oxford University Press; 2006. p. 13-22.

234

Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough

pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;

5: 327-334.

235

Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS

Drugs 2012; 26(6): 509-535.

236

Soares LG, Chan VW. The rationale for a multimodal approach in the management of

breakthrough cancer pain: a review. Am J Hosp Palliat Care 2007; 24(5): 430-439.

237

Stannard C. Stimulation-induced analgesia in cancer pain management. In: Sykes N, Fal-

lon MT, Patt RB (Hrsg.), Clinical Pain Management: Cancer Pain (pp. 245-251). London:

Edward Arnold, 2003.

238

Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and

pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiol 1998; 88: 305-309.

239

Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-

malignant diseases: A review of prevalence, characteristics and mechanisms. Eur J Pain.

2005; 9: 195-206.

240

Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a

survey of hospice patients on admission. Palliative Medicine 2001; 15: 9-18.

241

Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R; Fentanyl Pectin

Nasal Spray 043 Study Group. Fentanyl pectin nasal spray in breakthrough cancer pain.

J Support Oncol 2010; 8(4): 184-190.

242

Taylor DR, Gabrail N. Fentanyl pectin nasal spray for breakthrough cancer pain. Future

Oncol 2012; 8(2): 121-130.

Literaturverzeichnis